Silo Pharma

SILO

Market cap $4.73M

Silo continues to add technology assets as it expands its AI business and further develops its lead PTSD therapeutic candidate

Silo Pharma Incs (NASDAQ:SILO) announced on Tuesday that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices Inc.'s (NASDAQ:AMD) AI Developer Program, providing access to cloud computing credits, AI development tools, training resources, and a global developer network aimed at accelerating the platform's growth.

Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agents Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agents

$4 million upfront with up to approximately $7.7 million of potential additional gross proceeds upon the exercise in full of warrants in cash

NVIDIA Corp. (NASDAQ:NVDA) expanded its presence in life sciences AI through separate initiatives with Certara Inc. (NASDAQ:CERT) and Silo Pharma Inc. (NASDAQ:SILO).

NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing

Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system

Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has confirmed the physical, chemical and microbiological stability of its investigational soft-mist intranasal prophylactic, SPC-15, through nine months of real-time testing.

SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC informing the Company that, as of June 17, 2026, it has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). Silo's common stock continues to trade on the Nasdaq Capital Market, and the matter is now closed.

New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines